Peptide LexiconAll compounds

Cardiogen (Ala-Glu-Asp-Arg): The Four-Amino-Acid 'Heart Bioregulator' and the Three Other Things That Share Its Name

Cardiogen is a synthetic tetrapeptide, given as Ala-Glu-Asp-Arg (AEDR), from the St Petersburg bioregulator programme, sold for the heart. PubMed returns 19 records for the word; four concern the peptide, all in rat tissue, rats or cultured cells. Six concern CardioGen-82, an unrelated heart-scan product. No human study of the peptide is indexed.

Not approved anywhere this entry foundNo human study indexedName shared with unrelated products

Caroline S · Published 2026-11-13

Length

4 amino acids — C18H31N7O9, molecular weight about 489.5 (our arithmetic from the four residues; PubChem has no record under either name)

Sequence

AEDR (Ala-Glu-Asp-Arg)

Origin

Synthetic; one of the organ-labelled short peptides made in St Petersburg by V. Khavinson's bioregulation and gerontology institute — the heart-labelled member

Last reviewed

2026-11-13

What is it good for?

Sellers present it as a bioregulator for the heart. No human study of it is indexed in PubMed and none is registered. The four indexed studies used rat heart tissue in culture, rats with transplanted tumours, and cultured human prostate cells. A reader searching the name will also meet CardioGen-82, an FDA-approved rubidium generator for heart scans, which is a different thing entirely.

Illustration: Four clear glass vials with white powder on a white surface, with green and copper accents.
Illustration

What it is

Cardiogen is a synthetic peptide of four amino acids: alanine, glutamic acid, aspartic acid and arginine. The St Petersburg laboratory led by V. Khavinson, which names each of its short synthetic peptides after an organ, assigns this one to the heart. Its relatives in this library include epitalon, the programme's best-known tetrapeptide, and vesugen, its blood-vessel tripeptide.

How sure is the sequence? The study abstracts that name cardiogen call it "the synthetic tetrapeptide cardiogen" without printing the letters. The pairing of the name with AEDR comes from the programme's own 2021 review (PMID 34834147), whose full text holds both terms. A 2013 paper lists Ala-Glu-Asp-Arg among six short peptides tested on wheat histones, without the trade name (PMID 23581987). Epitalon is Ala-Glu-Asp-Gly, so the two differ only in the last amino acid.

PubChem has no record for the peptide under either name. The formula C18H31N7O9 and the weight of about 489.5 in this entry are our arithmetic from the four residues, not a database value.

Change the last residue and the series moves to another organ: Ala-Glu-Asp-Leu is Bronchogen, the lung-labelled tetrapeptide, and Ala-Glu-Asp-Pro is Cortagen.

Three other things called cardiogen

A search for this name returns more noise than signal, and the confusion matters.

Name What it is Where it turned up
CardioGen-82 A strontium-82/rubidium-82 generator for PET scans of the heart, FDA-approved, recalled in 2011 over strontium exposure 6 of the 19 PubMed records; 1 ClinicalTrials.gov study (NCT01424774)
CARDIOGEN A French clinical network for inherited heart disease; also a Hungarian registry PubMed records from 2017 and 2025
"cardiogen" as a synonym PubChem resolves the word to a carnitine record (CID 10917, C7H15NO3) PubChem name search, 2026-11-13

None of these is the peptide.

What the research shows

A PubMed search on 2026-11-13 returned 19 records with "cardiogen" in the title or abstract. By this entry's reading of the abstracts, four concern the peptide.

Year Model What the abstract reports PMID
2006 Tissue cultures from young and old rats Cardiogen and three related peptides stimulated their matching tissues at 0.05 ng/ml 17152728
2009 Heart-muscle explants from 3- and 24-month-old rats Stimulated cell proliferation in both ages; lower p53 expression, which the authors read as less cell death 20210190
2009 Old rats with transplanted M-1 sarcoma Dose-dependent slowing of tumour growth, with bleeding tissue death and more tumour-cell death; the authors point to the tumour's blood vessels 20396706
2010 Ageing cultures of human prostate fibroblasts Three peptides raised signalling markers; a different peptide, T-38, was "the most active" 20586252

Two points the table does not show. The first three studies are rat work; the fourth used human cells in a dish, not people. And the 2009 pair pulls in opposite directions on the page: one reports more cell growth in heart tissue, the other more cell death in a tumour. The authors do not treat these as contradictory, but no independent group has tested either.

What is not established

  • A heart effect in a living person. Every result above comes from rat tissue, rats or a dish of prostate cells; the heart-muscle finding is cell proliferation in explants, which is not the same thing as a working heart pumping better.
  • Which way the growth signal cuts. More proliferation in heart explants and more cell death in a sarcoma were reported from the same programme in the same year. Whether one peptide can do both in one body was never tested.
  • Any human safety record. Nobody has reported giving cardiogen to people, so there is no figure for side effects at any amount.
  • That AEDR arrives where it is aimed. None of the four abstracts follows the tetrapeptide after it is given, so whether it reaches heart muscle intact is unknown. The series' other tetrapeptide sold for an organ, Prostamax, has a record made up entirely of chromatin studies.
  • Confirmation by another laboratory. No study from outside the originating programme is indexed, and nothing at all has appeared on the peptide since 2010.

Where it stands

  • Regulatory status: no approval of the AEDR peptide found; the approved product with the same-sounding name is the CardioGen-82 scan generator, which is not a peptide.
  • Where readers meet it: research-chemical listings and multi-peptide bioregulator blends sold for the heart. Products are outside this library's scope.
  • Size of the record (2026-11-13): four peptide papers, 2006–2010, none since; of four ClinicalTrials.gov name matches, none studies the peptide.

The shortest member of the family is Vilon, a dipeptide, and the reproductive-labelled one is testagen. Peptides the heart itself makes are described in the natriuretic peptides entry. For how longevity claims for this family compare with their human evidence, see the longevity overview.

What the research shows

Stimulates heart-tissue growth

Chalisova et al. 2009 (PMID 20210190): rat heart-muscle explants in culture, young and old animals; Zakutskii et al. 2006 (PMID 17152728): rat tissue cultures — laboratory only

Slows tumour growth

Levdik et al. 2009 (PMID 20396706): rats with transplanted M-1 sarcoma — animal only

Restores signalling in ageing cells

Kheifets et al. 2010 (PMID 20586252): cultured human prostate fibroblasts; another peptide in the study was the most active

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

No approval found for the peptide. The approved product with a near-identical name, CardioGen-82, is a rubidium-82 generator used in heart imaging.

Trials

ClinicalTrials.gov: 4 matches for 'cardiogen', none of them the peptide (2026-11-13).

Published record

PubMed: 19 records with 'cardiogen' in the title or abstract; 4 concern the peptide (2006–2010), 6 concern CardioGen-82, and the rest use the word in other senses (our reading of the abstracts, 2026-11-13).

Frequently asked questions

What is Cardiogen?

A synthetic four-amino-acid peptide — alanine, glutamic acid, aspartic acid, arginine — from the St Petersburg peptide bioregulator programme. Sellers present it for the heart.

Is Cardiogen the same as CardioGen-82?

No. CardioGen-82 is a rubidium-82 generator used in hospital PET scans of the heart. It shares a name with the peptide and nothing else.

Has Cardiogen been tested in humans?

No human study of the peptide is indexed in PubMed, and ClinicalTrials.gov lists none (2026-11-13). The four indexed studies used rat tissue, rats and cultured cells.

What does the research on Cardiogen show?

In culture, it stimulated cell growth in rat heart-muscle explants. In rats with a transplanted sarcoma, injections were followed by slower tumour growth. These are animal and laboratory findings from one research programme.

Is Cardiogen approved?

No regulator has approved the peptide in any record this entry found; the approved product called CardioGen-82 is a rubidium generator used in heart scans. The peptide itself is offered by research-chemical sellers and inside bioregulator blends, which this library does not assess.

What is Cardiogen's sequence?

Ala-Glu-Asp-Arg, written AEDR. The older study abstracts call it only 'the synthetic tetrapeptide cardiogen'; the sequence is paired with the name in the programme's 2021 review.